GlassScriptPhysician profile
Thomas F Cook
NPI 1427054477
$6,273.36
in general payments reported to CMS, 2019-2025
21 companies · $622 in 2025
The $622 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $429 · 2021: $790 · 2022: $1,147 · 2023: $1,220 · 2024: $1,244 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.36 |
| Education | $214.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.02 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,115.61 | 2019-2025 | Tremfya |
| Ucb, INC. | $470.74 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $394.28 | 2022-2023 | Opzelura, Iclusig |
| Galderma Laboratories, L.P. | $392.55 | 2019-2024 | Epsolay, Aklief, Twyneo |
| Amgen INC. | $382.94 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $289.43 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $204.50 | 2019-2025 | Blu-U |
| Arcutis Biotherapeutics, INC. | $200.78 | 2024 | Zoryve |
| Genzyme Corporation | $197.04 | 2019-2023 | |
| Biofrontera INC. | $172.93 | 2019-2025 | Rhodoled Xl, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $152.29 | 2021-2024 | Jublia, Cabtreo, Arazlo |
| Pfizer INC. | $151.48 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $151.30 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $142.34 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $123.76 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $101.65 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $66.64 | 2020-2021 | |
| Lilly USA, LLC | $24.66 | 2024 | Olumiant, Taltz |
| Aclaris Therapeutics, INC. | $18.65 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.77 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.